MLchartDataset catalogue

allogeneic TGFBR2 KO CAR27/IL-15-expressing NK cells

Term · Oncology and biomedicine · MLC-T-ONC-009949

A preparation of allogeneic, umbilical cord blood (CB)-derived natural killer cells (NKs) that have been engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human cluster of differentiation 70 (CD70) and expressing the cytokine interleukin-15 (IL-15) and in which the gene transforming growth factor-beta receptor II (TGFbRII; TGFBR2) is deleted through clustered regularly interspaced short palindromic repeats (CRISPR)-Cas 9 gene editing, with potential immunostimulating and antineoplastic activities. Upon administration, the allogeneic TGFBR2 KO CAR27/IL-15-expressing NK cells target, bind to and induce selective cytotoxicity in CD70-expressing tumor cells. CD70, the ligand for the costimulatory receptor CD27, is overexpressed on the surfaces of various cancer cell types. IL-15 is a pro-survival cytokine that promotes persistence of multiple lymphocyte lineages and potentiates the immune response against tumor cells. As TGF-beta activation and release leads to NK cell inactivation, deletion of the TGFBR2 gene increases the potency, persistence and efficacy of the NK cells and enhances anti-tumor activity.

Table 1. Record
IdentifierMLC-T-ONC-009949
FieldOncology and biomedicine
Synonymsallogeneic TGFBR2 KO CAR27/IL-15-expressing natural killer cells; TGFBR2 knockout CAR27/IL-15 NK cells; TGFBR2 KO CAR27/IL-15 NK cells; TGFBR2 KO CAR27/IL-15 NKs
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-009949",
  "term": "allogeneic TGFBR2 KO CAR27/IL-15-expressing NK cells",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of allogeneic, umbilical cord blood (CB)-derived natural killer cells (NKs) that have been engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human cluster of differentiation 70 (CD70) and expressing the cytokine interleukin-15 (IL-15) and in which the gene transforming growth factor-beta receptor II (TGFbRII; TGFBR2) is deleted through clustered regularly interspaced short palindromic repeats (CRISPR)-Cas 9 gene editing, with potential immunostimulating and antineoplastic activities. Upon administration, the allogeneic TGFBR2 KO CAR27/IL-15-expressing NK cells target, bind to and induce selective cytotoxicity in CD70-expressing tumor cells. CD70, the ligand for the costimulatory receptor CD27, is overexpressed on the surfaces of various cancer cell types. IL-15 is a pro-survival cytokine that promotes persistence of multiple lymphocyte lineages and potentiates the immune response against tumor cells. As TGF-beta activation and release leads to NK cell inactivation, deletion of the TGFBR2 gene increases the potency, persistence and efficacy of the NK cells and enhances anti-tumor activity.",
  "synonyms": [
    "allogeneic TGFBR2 KO CAR27/IL-15-expressing natural killer cells",
    "TGFBR2 knockout CAR27/IL-15 NK cells",
    "TGFBR2 KO CAR27/IL-15 NK cells",
    "TGFBR2 KO CAR27/IL-15 NKs"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/allogeneic-tgfbr2-ko-car27-il-15-expressing-nk-cells/"
}

Record 836 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.